162 related articles for article (PubMed ID: 37679647)
21. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
Hernández-Boluda JC; Pereira A; Kröger N; Beelen D; Robin M; Bornhäuser M; Angelucci E; Vitek A; Blau IW; Niittyvuopio R; Finke J; Cornelissen JJ; Passweg J; Dreger P; Petersen E; Kanz L; Sanz J; Zuckerman T; Zinger N; Iacobelli S; Hayden P; Czerw T; McLornan D; Yakoub-Agha I
Leukemia; 2021 Jan; 35(1):215-224. PubMed ID: 32286544
[TBL] [Abstract][Full Text] [Related]
22. Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis.
Cyriac S; Prem S; Salas MQ; Chen S; Al-Shaibani Z; Lam W; Law A; Gupta V; Michelis FV; Kim DDH; Lipton J; Kumar R; Mattsson J; Viswabandya A
Eur J Haematol; 2021 Nov; 107(5):517-528. PubMed ID: 34260760
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.
Schmohl JU; Groh C; Faul C; Vogel W; Möhle R; Wirths S; Schneidawind D; Kanz L; Bethge WA
Ann Hematol; 2016 May; 95(6):973-83. PubMed ID: 27021303
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
26. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
28. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.
Daghia G; Zabelina T; Zeck G; von Pein UM; Christopeit M; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2019 Oct; 103(4):370-378. PubMed ID: 31306511
[TBL] [Abstract][Full Text] [Related]
31. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
[TBL] [Abstract][Full Text] [Related]
32. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
Hernández-Boluda JC; Pereira A; Alvarez-Larran A; Martín AA; Benzaquen A; Aguirre L; Mora E; González P; Mora J; Dorado N; Sampol A; García-Gutiérrez V; López-Godino O; Fox ML; Reguera JL; Pérez-Encinas M; Pascual MJ; Xicoy B; Parody R; González-Pinedo L; Español I; Avendaño A; Correa JG; Vallejo C; Jurado M; García-Cadenas I; Osorio S; Durán MA; Sánchez-Guijo F; Cervantes F; Piñana JL
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2237-2244. PubMed ID: 32717433
[TBL] [Abstract][Full Text] [Related]
33. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
34. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
35. Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation.
Zhu P; Lai X; Liu L; Shi J; Yu J; Zhao Y; Yang L; Yang T; Zheng W; Sun J; Wu W; Zhao Y; Cai Z; Huang H; Luo Y
J Transl Med; 2024 Mar; 22(1):275. PubMed ID: 38481248
[TBL] [Abstract][Full Text] [Related]
36. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A; Cerny J; Chhabra S; DeFilipp Z; Dholaria B; Perez MAD; Farhan S; Freytes CO; Gale RP; Ganguly S; Gupta V; Grunwald MR; Hamad N; Hildebrandt GC; Inamoto Y; Jain T; Jamy O; Juckett M; Kalaycio M; Krem MM; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Ortí G; Patel SS; Van der Poel M; Rizzieri DA; Savani BN; Seo S; Solh M; Verdonck LF; Wirk B; Yared JA; Nakamura R; Oran B; Scott B; Saber W
Haematologica; 2023 Jul; 108(7):1900-1908. PubMed ID: 36779595
[TBL] [Abstract][Full Text] [Related]
37. Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
Ecsedi M; Schmohl J; Zeiser R; Drexler B; Halter J; Medinger M; Duyster J; Kanz L; Passweg J; Finke J; Bethge W; Lengerke C
Ann Hematol; 2016 Oct; 95(10):1627-36. PubMed ID: 27480090
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Nabergoj M; Eikema DJ; Koster L; Platzbecker U; Sockel K; Finke J; Kröger N; Forcade E; Nagler A; Eder M; Tischer J; Broers AEC; Kuball J; Wilson KMO; Hunault-Berger M; Collin M; Russo D; Corral LL; Helbig G; Mussetti A; Scheid C; Gurnari C; Raj K; Drozd-Sokolowska J; Yakoub-Agha I; Robin M; McLornan DP
Bone Marrow Transplant; 2024 Mar; 59(3):395-402. PubMed ID: 38195984
[TBL] [Abstract][Full Text] [Related]
39. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
40. Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups.
Garcia-Horton A; Cyriac SL; Gedde-Dahl T; Floisand Y; Remberger M; Mattsson J; Michelis FV
Eur J Haematol; 2022 Dec; 109(6):672-679. PubMed ID: 36028979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]